1. Home
  2. TCPC vs TRDA Comparison

TCPC vs TRDA Comparison

Compare TCPC & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock TCP Capital Corp.

TCPC

BlackRock TCP Capital Corp.

HOLD

Current Price

$3.25

Market Cap

280.2M

Sector

Finance

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$6.46

Market Cap

268.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCPC
TRDA
Founded
2006
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
280.2M
268.6M
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
TCPC
TRDA
Price
$3.25
$6.46
Analyst Decision
Sell
Strong Buy
Analyst Count
2
3
Target Price
$3.50
$21.00
AVG Volume (30 Days)
874.8K
345.9K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
18.23%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$25,421,000.00
Revenue This Year
N/A
$39.97
Revenue Next Year
N/A
$50.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.08
$4.93
52 Week High
$7.74
$16.45

Technical Indicators

Market Signals
Indicator
TCPC
TRDA
Relative Strength Index (RSI) 42.49 40.81
Support Level $3.10 $5.75
Resistance Level $3.54 $7.02
Average True Range (ATR) 0.12 0.46
MACD 0.02 -0.06
Stochastic Oscillator 27.38 14.92

Price Performance

Historical Comparison
TCPC
TRDA

About TCPC BlackRock TCP Capital Corp.

BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: